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Abstract
Introduction A mobile app may increase the reporting of
adverse drug reactions (ADRs) and improve the commu-
nication of new drug safety information. Factors that
influence the use of an app for such two-way risk com-
munication need to be considered at the development stage.
Objective Our aim was to reveal the factors that may
influence healthcare professionals (HCPs) and patients to
use an app for two-way risk communication.
Methods Focus group discussions and face-to-face inter-
views were conducted in the Netherlands, Spain and the
UK. Patients with type 2 diabetes mellitus, patients with a
rare disease or their caregivers and adolescents with health
conditions were eligible to participate. HCPs included
pharmacists, paediatricians, general practitioners, inter-
nists, practice nurses and professionals caring for patients
with a rare disease. Patients and HCPs were recruited
through various channels. The recorded discussions and
interviews were transcribed verbatim. The dataset was
analysed using thematic analysis and arranged according to
the Unified Theory of Acceptance and Use of Technology.
Results Seven focus group discussions and 13 interviews
were conducted. In total, 21 HCPs and 50 patients partici-
pated. Identified factors that may influence the use of the app
were the type of feedback given on reported ADRs, how
ADR reports are stored and the type of drug news. Also
mentioned were other functions of the app, ease of use, type
of language, the source of safety information provided
through the app, security of the app, layout, the operating
systems on which the app can be used and the costs.
Conclusions Further research is needed to assess associa-
tions between user characteristics and the direction (positive
or negative) of the factors potentially influencing app use.
Key Points
Factors influencing the use of an app for two-way
risk communication concern what feedback would
be given on adverse drug reaction reports and how
safely these are stored and handled; what type of
news, if any, would be provided through the app;
other functions of the app; ease of use; the source
(authority) behind the app; appropriate language and
appeal of the app; and costs.
User characteristics (e.g. age, education, experience
with apps) may moderate to what extent specific
factors (e.g. functions, security) influence use of the
app.
When designing or improving an app for two-way
risk communication, pharmacovigilance experts, and
app researchers and developers should consider the
identified factors.
The Web-RADR work package 3b representatives are listed in
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1 Introduction
Although the efficacy and safety of a drug has been
assessed during the pre-marketing phase, post-marketing
surveillance is particularly needed to complement the
drug’s safety profile [1–3]. In post-marketing surveillance,
spontaneous reporting of adverse drug reactions (ADRs) to
the national regulatory agency has been the leading method
for decades [4]. Previously, ADRs were primarily reported
by healthcare professionals (HCPs). Over time, interest in
ADRs submitted directly by patients increased with the
recognition of the added value of patient reports [5–7]. In
many countries, patients are now allowed to report ADRs
to spontaneous reporting systems [8]. A major limitation of
spontaneous reporting, however, is that many ADRs go
unreported. There are multiple reasons for this, especially
time constraints and uncertainty about the causal relation-
ship between an experienced symptom and a drug [9–14].
In addition, many patients state that they are not aware of
the possibility of reporting an ADR to the national regu-
latory agency [10]. Moreover, patients may experience
recall problems when too much time has passed between
the onset of an ADR and reporting it [15].
Nevertheless, from time to time, spontaneously reported
ADRs and other current post-marketing surveillance
methods result in the detection of new safety signals that
change the benefit–harm profile of the drug [16]. Subse-
quently, HCPs need to be informed. Throughout the EU,
important new drug safety issues are primarily communi-
cated by sending paper-based warning letters directly to
HCPs [16]. In addition, many regulatory authorities publish
these safety issues on their website. However, it is apparent
from previous studies that new safety issues do not always
reach the HCP nor affect clinical behaviour [17, 18]. It is
also recognised that patients need to be informed about the
safety issues of drugs that are prescribed to them [19]. This
promotes patient involvement, and informed and shared
decision making in their treatment [20].
Recent technological developments such as mobile apps
may increase ADR reporting and improve the communi-
cation of new safety issues. The combination of reporting
ADRs and receiving safety information is known as two-
way risk communication. An app developed for two-way
risk communication may reduce the time between experi-
encing and reporting an ADR and may lead to more
informed patients and HCPs. The Web-Recognizing
Adverse Drug Reactions (Web-RADR) project (https://
web-radr.eu/) started with the development, testing and
implementation of an app for two-way risk communication.
The Web-RADR project aims to improve traditional
pharmacovigilance activities by using new tools to identify
potential new ADRs earlier (social media mining and the
mobile app) and to improve drug safety communication
(mobile app). The project has been described elsewhere in
more detail [21]. The app developed for the Web-RADR
project is intended for both patients and HCPs. In an app’s
development, involvement of end users is important to
ensure that their opinions and values are taken into
account. This will improve acceptance of the app [22].
Previous studies have been conducted to identify factors
that may influence the use of mobile apps on, for instance,
managing obesity [23] and diabetes mellitus [24] or pre-
venting sexually transmitted infections and drug abuse in
adolescents [25]. These studies show that app use will be
influenced by factors such as ease of use, layout, and
security of the data held in the app.
The aim of the current study was to identify factors
which HCPs and patients suggested could influence their
use of a mobile app for two-way drug risk communication.
Findings from this study will be of interest to pharma-
covigilance experts (regulatory agencies, industry and
academics), and app researchers and developers.
2 Methods
2.1 Study Design
We performed a qualitative, multi-country study to identify
the factors that may influence the use of an app for two-
way risk communication in different patient and HCP
groups (Table 1). The qualitative methods used were focus
group discussions and face-to-face interviews. Countries
involved were the Netherlands, Spain, and the UK. Ethical
approval for this study was sought as determined by each
country’s local ethics committee policy. Informed consent
was obtained from all participants.
2.2 Population
Patients with type 2 diabetes, patients with a rare disease
(e.g. familial Mediterranean fever, narcolepsy) or their
caregivers, and adolescents with health conditions were
included in this study. These patient groups were selected
to cover a wide variety of potential factors influencing the
use of an app in a population that differed with respect to
age, treatment options, and disease and treatment burden.
An equally diverse group of HCPs serving these popula-
tions was recruited: pharmacists, professionals linked to
patients with a rare disease, paediatricians, general practi-
tioners (GPs), internists and practice nurses. Inclusion
criteria for all participants were being able to speak, read
and write the local language, owning a smartphone or
tablet, being able to use such technology, and providing
informed consent. In the case of adolescents aged B16
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years, a parent or guardian had to provide informed con-
sent. A specific inclusion criterion for patients was that
they had ever experienced (or detected, in the case of
caregivers) an ADR from any drug they (or their child) had
used. Participants were recruited through various channels
such as advertisements on websites and direct contact via
patient and HCP organizations (Online Resource 1, see
electronic supplementary material). Most of the partici-
pants received some form of compensation (Table 1).
2.3 Procedure
The focus group discussions and face-to-face interviews
were led by one of the researchers (STdV in the Nether-
lands, CLR in Spain, and LW in the UK). Some of these
researchers had previous experience with qualitative
research and all attended a 1-day face-to-face training led
by an expert in qualitative research. The discussions and
interviews consisted of three steps (adapted from [26]): (1)
an introduction, (2) discussion about factors potentially
influencing the use of an app for two-way risk communi-
cation in general and (3) opinions about and influencing
factors for a prototype version of the Web-RADR app.
During the first step, participants completed a consent form
and provided baseline characteristics: age, gender and
educational level (for patients), or profession (specialisa-
tion of HCP). A semi-structured guide was used during the
second and third step (Online Resource 2, see electronic
supplementary material). On average, the duration of the
focus group discussions and face-to-face interviews was
approximately 90 min. Focus group discussions and face-
to-face interviews were conducted until theoretical satu-
ration was reached. Theoretical saturation means that no
new topics appear and all aspects of a theory are covered
[27]. All data collected from the discussions and interviews
across all countries were used in this assessment.
2.4 Web-RADR App Prototype
The prototype version of a mobile app for two-way risk
communication was developed by the Web-RADR con-
sortium for iOS and Android devices. The prototype was
developed in English and translated to Dutch and Spanish
versions for use in this study. To access the app, users had
to enter an e-mail address and password on a login screen
(Fig. 1a). The app contained two major functions: the
ability to report ADRs (Fig. 1b) and to receive news on
drug safety issues (Fig. 1c). In addition, users were able to
view a graphical presentation of the number of reported
ADRs per drug (Fig. 1d).
During the focus group discussions and face-to-face
interviews, participants used the prototype app on a device
provided by the researchers. In some cases (e.g. no internet
connection), screenshots of the app were presented. In sit-
uations where the screenshots were used, this did not deter
lively discussion. Participants were asked to go through the
app and report any problems or issues they detected. These
app-specific comments and suggestions have been reported
Table 1 Methods per patient population
Patients HCPs Country Study design Compensation Ethical
approval
Recording
Patients with
T2DM
General
practitioners;
Internists;
Pharmacists;
Practice nurse
The Netherlands Face-to-face
interviews
HCPs received a voucher of €75 for
their participation. Patients received
a voucher of €50
UMCG
(reference
number
M15.172178)
Video
Patients with a
rare disease
and
caregivers of
such patients
HCPs from the
Hospital Sant
Joan de De´u
from Barcelona
Spain Focus group
discussions
Participants were compensated for
their time and travel, according to
the established budget for the
EURORDIS involvement in the IMI
Web-RADR project
Fundacio´ Sant
Joan de De´u
Audio
Adolescents Lead Pharmacist
Medication
Safety;
Paediatricians;
Hospital doctors
UK Face-to-face
interview
and focus
group
discussions
Adolescents were compensated travel
expenses and refreshments/lunch for
participating in the focus groups. A
thank-you letter was sent to each
adolescent following the session.
Paediatricians, hospital doctors and
pharmacists were not offered any
compensation
UCL Research
Ethics
Committee
Audio
EURORDIS European Organisation for Rare Diseases, HCPs healthcare professionals, IMI Innovative Medicines Initiative, T2DM type 2
diabetes mellitus, UCL University College London, UK United Kingdom, UMCG University Medical Center Groningen, Web-RADR Web-
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Fig. 1 Screenshots of the UK
version of the prototype app for
two-way risk communication.
a Login screen, b first screen to
report an adverse drug reaction
(ADR), c example of news
items, d overview of reported
ADRs
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to the Web-RADR consortium to improve the app. Fol-
lowing review of the app, the semi-structured guide was
used to determine any additional factors that may influence
the use of a mobile app for two-way risk communication
based on the participants’ experience with the prototype
version of the app.
2.5 Analyses
The focus group discussions and face-to-face interviews
were video- or audio-recorded (Table 1) and transcribed
verbatim by one of the researchers. The transcripts were
analysed by one researcher (Spain) or two researchers (the
Netherlands and the UK) using thematic analysis in which
themes or patterns were identified using a deductive (top-
down)/theoretical approach [28]. The theoretical model
used for this analysis was the Unified Theory of Accep-
tance and Use of Technology (UTAUT) [29]. This model
states that factors related to performance expectancy, effort
expectancy, social influence and facilitating conditions
influence users’ intention to use an app and whether they
will actually use it [29]. In addition, gender, age, experi-
ence and voluntariness of use are described as moderating
variables in the model. The analyses of the three countries
were integrated into one overall report developed by one of
the researchers and checked by all others to reduce any
biases.
3 Results
In total, seven focus group discussions and 13 face-to-face
interviews were conducted in which 21 HCPs and 50
patients participated (Online Resource 3, see electronic
supplementary material). Of the participating HCPs, ages
ranged from 29 years old in the UK to 60 years old in
Spain. Most of the HCPs were female (range from 50% in
the Netherlands to 75% in the UK). The age of partici-
pating patients ranged from 11 years old in the UK to 67
years old in Spain. Most of the patients were female,
ranging from 57% in Spain to 77% in the UK.
3.1 Factors Influencing the Use of an App for Two-
Way Risk Communication
Several factors and moderating variables that may influ-
ence the use of an app for two-way risk communication
were raised during the focus group discussions and face-to-
face interviews. A summary of these identified influencing
factors and moderating variables is presented in Fig. 2. In
the following sections, the identified influencing factors are
described per theme of the UTAUT model.
3.1.1 Performance Expectancy
3.1.1.1 Feedback Participants indicated that it should be
possible to provide feedback on the app.
‘‘… make sure that there is something of, if necessary
even a link in case the app doesn’t work well; report
this through this link. Or comments about the app;
report this through this link. That people can mention
it somewhere’’ (the Netherlands, Patient 4).
Most of the participants preferred some kind of feedback
after submitting an ADR report. This ranged from a simple
confirmation that the report was successfully sent, to an over-
viewof howoften this type ofADRhas been reported earlier, to
receiving feedback onwhat ultimatelywas donewith the report
(e.g. whether the report resulted in a new safety signal).
‘‘Basically, what I would like to have is feedback
what happened with the reports I have previously
submitted through the app’’ (Spain, focus group with
patients and their carers).
In a UK focus group with adolescents, concerns were
raised that feedback might come too late if the ADR was
serious. In this group a suggestion was made that a serious
ADR could be flagged in the GPs’ electronic prescribing
system alerting them to contact the patient. [Of note, this is
a function currently not foreseen for the app.]
Some participants, however, saw feedback as annoying.
Suggestions were made to provide checkboxes where app
users could indicate if they wish to receive feedback.
3.1.1.2 Storage of Reports Most of the participants pre-
ferred an option to access their earlier reported ADRs and
to store unfinished reports to complete later.
3.1.1.3 News in the App There were some opposing
views on news items in the app. Some participants felt that
news could be useful.
‘‘I think that this can be a fast way to inform end-
users, prescribers about new information that is
known about it’’ (the Netherlands, HCP 8).
However, others felt that there was already too much
information
‘‘There is so much information being constantly gen-
erated, that we are not able to take up such amount of
information’’ (Spain, focus group with HCPs)
and that the app’s goal should simply be to report ADRs
‘‘I would not directly link it [drug safety information]
to the app to my feeling, you have other sources for
that’’ (the Netherlands, HCP 2).
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Some suggestions were offered for types of news items
that would be of interest, such as newly identified ADRs of a
drug, changes in the frequency of an ADR with a drug (e.g.
from rarely to often), new drug–drug interactions, the issu-
ance of Direct Healthcare Professional Communications
(DHPCs or dear doctor letters), drugs taken off the market,
newly marketed drugs or new applications of a drug, and
changes in guidelines. However, not everyone was interested
in all types of information. Some preferred to receive infor-
mation for all drugs whereas others were interested only in
those they took or prescribed themselves. Therefore, partic-
ipants suggested app users should be able to personalise the
type of information they wanted to receive news about.
News or information in the app may empower patients
to communicate with their HCP, for instance, by increasing
patients’ confidence in a symptom being an ADR.
‘‘People who do not have the medical knowledge can
have a look at their phone and they can see that it
happens more often [a specific symptom], so I can
discuss it with my doctor’’ (the Netherlands, Patient 3).
It might also help patients determine whether a symptom
is an ADR, particularly if an HCP is not aware of the
association.
Some patients indicated that they did not want to visit
their doctor for every symptom they had experienced. The
app may assist these patients to check whether these
symptoms could be related to a drug they use.
3.1.1.4 Other Functions Several other functions were
reported as useful for this type of app. An example was
providing drug product information in the app. This may,
however, negatively influence adherence since patients
may not want to take a drug when they read about ADRs
they may experience:
‘‘I personally would use it before I take a medicine,
also to see what sort of side effects I may get in case
it’s something severe I may not want to take the
medication’’ (the UK, focus group with patients).
Other examples of functions that were seen as useful
were the option to read about others’ experiences with a
drug and the option to add experiences (e.g. using a forum
or providing a link to a forum), an overview of alternative
drugs to the one where an ADR is experienced, alerts on
quality defects (added value for pharmacists and pre-
scribers), summary of guidelines, information about how to
resolve/alleviate the ADR, interactions between drugs, and
Performance expectancy:
* Feedback
* Storage of reports
* News in the app
* Other functions
Effort expectancy:
* Accessibility / ease of use
* Language
Social influence:
* Prestige / reliable, independent source and 
receiver
Facilitating conditions:
* Security / confidentiality of the data
* Layout
* Operating system, internet access
* Costs (tariff and memory)
Behavioural 
intention
Actual 
behaviour
Moderating variables:
E.g.:
- Age
- Experience 
- Educational level
- Cognitive skills
- Socio-economic status
- Level of interest
Fig. 2 Overview of the identified influencing factors and moderating variables of using an app for two-way risk communication
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a prediction model presenting the likelihood of a symptom
being an ADR after entering some information. The latter
would be useful not only for HCPs but also for patients.
‘‘If you were taking two medicines at the same time,
how would you decide which side effect belonged to
each drug?’’ (the UK, focus group with patients).
An option to store a list of (previously) prescribed drugs
in the app could be useful in clinical practice and in ADR
reports. In clinical practice, this could provide an up-to-
date drug list for HCPs that would be useful for both HCPs
and patients (the Netherlands, HCP 4). In ADR reports, the
drug list could be added to check whether co-medication
might have impacted a reported ADR instead of a single
causative drug entered by the patient (the Netherlands,
Patient 4).
Discrepant opinions were given on, for instance, a
reminder function in the app. Some participants thought it
would be useful to have a reminder function to report an
ADR, to go to an appointment with an HCP, or to take
drugs (the UK, focus group with patients). Others found a
reminder function for taking prescribed drugs irrelevant
(the Netherlands, Patient 2).
3.1.2 Effort Expectancy
3.1.2.1 Accessibility/Ease of Use An app was seen as an
easily accessible tool for two-way risk communication.
‘‘You are immediately there where you have to be,
you don’t have to search on Google, you don’t have
to use paper and pen, you don’t have to call’’ (the
Netherlands, Patient 4).
However, participants indicated that information about
the existence of the app would have to be widely circu-
lated, as there are too many apps available.
‘‘The problem with apps is that there are so many that
you don’t overlook it’’ (the Netherlands, HCP 5).
Some keywords describing a successful app were pro-
posed: easy, simple, short, clear, logical. An app may
increase the reporting of ADRs since time constraints were
often mentioned by HCPs as an important factor for not
reporting an ADR (the Netherlands, HCPs 3–8). Patients
also mentioned time in relation to reporting an ADR.
‘‘If I had to input all the information, if it took a lot of
time I don’t think I will [use it]’’ (the UK, focus
group with patients).
In general, apps that do not meet the above-mentioned
criteria were considered not likely to be used or to be used
again.
Appreciated functions were those considered to facili-
tate ease of use, such as lists with, for instance, drug names
that populate after entering a few letters, and options where
answers can be selected (click on and/or drop-down
options). For the latter, being able to input their answer or
at least to be able to type in a different answer to the one
offered was preferred. Inappropriate questions such as
asking males if they were pregnant were seen as annoying
and conveyed a feeling of not being taken seriously. A
concern was raised that a very easy-to-use app might lead
to over-reporting.
3.1.2.2 Language The language in the app was an
important influencing factor for using it. The terminology
in the app should be appropriate for HCPs and lay people.
‘‘I think you should there, say, what we all understand
in medical jargon is not understood by patients. [ex-
ample given]. On the other hand, I do not want a
thing [app] in which itching is mentioned [instead of
pruritus] and that kind of’’ (the Netherlands, HCP 6).
Some HCPs as well as patients indicated that it would be
useful to have the app in other languages.
‘‘It is of course super luxury, we have a multicultural
uh that it [the app] can also be used in English for
instance. Like: translate this app in English’’ (the
Netherlands, Patient 4).
3.1.3 Social Influence
3.1.3.1 Prestige/Reliable, Independent Source and Recei-
ver A clear link of the app to an organisation with good
standing or reputation would increase use of the app.
‘‘People will trust it more if they know it is from
[e.g.] NHS [National Health Service]’’ (the UK, focus
group with patients).
In addition, it was important to the participants that
ADR reports were sent to a reliable receiver, and that
information would be provided by a reliable source. The
source/receiver should be familiar to the potential app
users. In addition, app use among patients may be
increased if HCPs were to endorse it.
‘‘[if the app was] endorsed by a doctor then it [the
app] would be used a lot’’ (the UK, focus group with
patients).
A topic that specifically came up during the focus group
discussion with adolescents was whether parents should be
able to view their child’s ADR reports. In general, older
children preferred parents not to have access and younger
children wanted parents to be informed.
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3.1.4 Facilitating Conditions
3.1.4.1 Security/Confidentiality of the Data A safe app
was viewed as important.
‘‘I would like the app to have a security system to
protect the personal data provided in each user pro-
file’’ (Spain, focus group with patients and their
carers).
However, most participants did not appear to be too
concerned about security. They expected that no patient-
identifiable details would be required and that the data
would be handled confidentially.
‘‘I should of course say that it should be a safe net-
work etcetera, basically, you do not use the name of a
patient, you use sex, date of birth, so I do not see any
[security issues], no’’ (the Netherlands, HCP 1).
Storage of the report was seen as adequate when there
would be no patient-identifiable information or when
patient permission had been obtained (the Netherlands,
HCP 8).
Participants with, or involved in, the care of patients
with a rare disease, and adolescents seemed to be more
concerned about the security of the app and the personal
information in it. Some stated they would not use their real
name but ‘‘put in a false name’’ (the UK, focus group with
patients). Using login details each time they accessed the
app was seen as necessary added protection of their data.
‘‘People messing around on your phone can’t log onto
the account, so people can’t just get into it and send
random side effects’’ (the UK, focus group with
patients).
However, some participants found it annoying to have to
enter their login details each time they accessed the app
and they were less concerned about the security of data
stored in the app.
‘‘There are no big medical secrets in it’’ (the
Netherlands, Patient 3).
One suggestion made was that users would have the
option of saving their login details on their personal
devices.
3.1.4.2 Layout The layout of an app was seen as an
important influencing factor for whether people would use
the app and keep on using the app. In general, it was
suggested never to use very bright colours. Such colours
may, for instance, cause seizures in people with epilepsy.
One indication was that if the colours, as well as font type
and size, could be changed to one’s own preferences this
would facilitate the use of the app.
‘‘I think, I assume […], that you can change the
colours yourself’’ (the Netherlands, Patient 2).
Participants indicated that the logo of the app should be
recognisable and appealing. It should be clear from the
logo what function the app has, clearly linking the app to
the agency to which the ADR reports are sent.
3.1.4.3 Operating System, Internet Access It was sug-
gested that the app should be available for all operating
systems on mobile phones and tablets and that they should
have been tested on each system before the app is
launched.
‘‘If you develop an app you have to do it for all three
media. Apple, Android and Microsoft’’ (the Nether-
lands, HCP 4).
Adolescents were the only group who mentioned that it
should be possible to enter an ADR report into the app while
being ‘off-line’. It should be possible to send the report later
when ‘on-line’ and internet access became available. The
motivation for that may be related to the costs, meaning that
adolescents prefer to use freely available internet access on
their mobile phones rather than activating mobile internet
access for which they have to pay.
3.1.4.4 Costs (Tariff and Memory) Participants indicated
that the app should be free of charge to stimulate use. A
topic that was mentioned only by adolescents or HCPs
treating adolescents was the concern about the amount of
space the app took up on an individual’s device.
‘‘Will it clog up your phone’’, ‘‘take up loads of
memory’’, ‘‘how cumbersome or big is the app’’,
‘‘what is the size of sending an average response
(report). Is it in terms of just a few kilobytes?’’ (the
UK, focus group with HCPs).
3.2 User Characteristics
Several user characteristics are described in the UTAUT
model as moderating factors: age, gender, experience and
voluntariness of use. Age and experience were also men-
tioned in our study. Participants indicated that they
expected older people to be less likely to possess a mobile
phone or tablet, to be more often visually impaired and to
be generally less experienced with using apps than younger
people. These factors could affect whether such patients
will be reached through an app. It may also influence the
preferences of potential users on the app lay-out (e.g. font
size). In addition, it was mentioned that a user’s previous
experience with apps influences how easy they may find it
to use this app.
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In our study, other characteristics were also mentioned
as factors potentially influencing the use of the app.
Characteristics such as educational level, cognitive skills,
socio-economic status, ambition, duty, assertiveness,
curiosity, level of interest and anxiety were mentioned as
factors influencing not only being able to, daring to, or
willing to report ADRs through an app, but also for pos-
sessing a mobile phone or tablet, and having the knowledge
to use or look for information on an app.
3.3 Behavioural Intention
In general, participants were quite positive about an app for
two-way risk communication. They liked the idea and
indicated that there seems to be a need for it.
3.4 Factors Influencing Reporting an ADR
in General
The focus group discussions and face-to-face interviews
also revealed factors that may influence the reporting of an
ADR in general. These influencing factors are related to
knowledge, motivation and reporting of ADRs by patients.
3.4.1 Knowledge
There was a lack of knowledge among some patients about
the possibility of being able to report an ADR at all.
‘‘I didn’t know that reporting an adverse reaction to
medication was an option I had’’ (Spain, focus group
with patients and their carers).
Some were familiar with ADR reporting but seemed
unsure about which type of ADRs to report. This uncer-
tainty was also observed in HCPs who said that they would
report new ADRs, serious ADRs and any ADRs of a new
drug. Participants were unsure if less severe ADRs required
reporting.
‘‘Is this severe enough to report?’’, ‘‘or they should
say that you can report every ADR so that you don’t
have to think about whether this is something that
they intend to collect’’ (the Netherlands, Patient 4).
They also stated that the goal of collecting ADRs should
be clearly defined; for instance, whether it is about
detecting rare ADRs or to quantify further the frequency of
known ADRs.
3.4.2 Motivation
There was some discrepancy in motivation to report ADRs.
Most patients and HCPs indicated that reporting an ADR
should be based on intrinsic rather than extrinsic reasons.
‘‘We are professionals so we have a certain faith so to
speak’’ (the Netherlands, HCP 5).
‘‘If I knew that the app that I was inputting all this
information would benefit other people as well, then I
would’’ (the UK, focus group with patients).
However, there were also some HCPs who suggested
that extrinsic reasons might stimulate reporting. ADR
reporting was stated to always be additional to the regular
tasks and that it does not deliver any immediate benefits
(the Netherlands, HCP 8).
One HCP mentioned that comparing the number of
reported ADRs with colleagues (a kind of benchmarking)
could stimulate reporting in the future. Also, HCPs’ com-
parison with their previous reports may stimulate reporting.
‘‘In the last months, I always did 20 reports, this time
it was 2, what is the cause of that? So that is also to
stimulate to report’’ (the Netherlands, HCP 4).
3.4.3 Reporting of ADRs by Patients
It was mentioned that reporting an ADR might be less
cumbersome for patients than for HCPs. Thus, patients
could be asked more questions than HCPs (the Nether-
lands, HCP 7). However, this may be perceived differently
by some patient groups as adolescents indicated that they
did not like answering too many questions.
Some HCPs were worried about the quality of patient
reports. Therefore, quality checks were suggested, such as
inviting the HCP to also report the ADR for a particular
patient or to ask additional questions in the patient report
(e.g. whether it has been discussed with the HCP, whether
other causes have been examined). Specifically, HCPs
caring for patients with rare diseases indicated that reports
should be validated by an HCP before they are sent
elsewhere.
It was mentioned several times that linking the reports to
a patient’s clinical file would be useful. HCPs would
immediately be up-to-date when opening a patient’s clin-
ical file. Moreover, HCPs indicated that they would be
interested in what their patients had reported.
‘‘If patients were reporting ADRs of drugs I’d started
it would be useful to know. Definitely’’ (the UK,
focus group with HCPs).
A concern HCPs had was that patients might report the
ADR and take no further action.
‘‘Don’t want them to just report it and then carrying
on with their life…don’t want it to be a replacement
for seeing their HCP’’ (the UK, focus group with
HCPs).
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This concern seems justified since some adolescents
mentioned that reporting an ADR, for instance through the
app, might reduce the need for a verbal conversation with
an HCP, particularly in the case of embarrassing conditions
(e.g. emotional problems) (the UK, focus group with
patients).
4 Discussion
This study showed that HCPs and patients were generally
positive about using an app for two-way risk communica-
tion. Actual use of the app would be influenced by the type
of feedback given after an ADR has been reported; whether
ADR reports can be stored safely; and what type of news is
provided. Other, more general factors that may influence
actual use are other functions of the app; ease of use,
appropriate language and an attractive and possibly modi-
fiable layout; the source (authority) behind the app; the
security of the app; the operating systems on which the app
is available; and the costs of the app in terms of tariff and
memory. User characteristics such as age, experience,
educational level, cognitive skills and personality charac-
teristics were identified as potential moderating variables in
the association between identified factors and the intention
to use an app for two-way risk communication. Some
identified factors (e.g. availability of other functions,
security features) could both negatively and positively
impact the use of an app and further studies are needed to
determine how user characteristics influence this direction.
Some of the identified influencing factors apply partic-
ularly to an app for two-way risk communication. An
important example of such a factor is the receiver to whom
information is sent or the source of information provided
through to the app. For effective risk communication, trust
and/or confidence in the source/receiver are important [30].
Our results are similar to previous studies about app use
with respect to influencing factors such as ease of use,
language, layout, and costs [24, 31]. These can be seen as
general influencing factors for using any app.
The finding that user characteristics may influence the
use of an app for two-way risk communication is in
accordance with the UTAUT model, in which several user
characteristics are indicated as moderating variables.
Elderly people, for instance, tend to adopt more slowly or
reject technology [32] and may therefore have less
intention to use an app. A previous study about health-app
use also showed that user characteristics such as age,
income and educational level influence the use of apps
[33]. Further quantitative research is needed to assess
whether all the characteristics mentioned in our study
indeed influence the use of an app for two-way risk
communication.
One of the aims of an app for two-way risk communi-
cation is to improve the communication of new safety
information. Interestingly, some participants did not prefer
an app for two-way risk communication in the sense that it
contains both risk information and the option to report
ADRs. They indicated that the app should just focus on one
function, for instance ADR reporting. This finding might be
due to the previously demonstrated negative association
between the number of functions in an app and its usability
[34]. Therefore, close attention should be paid to the
usability of an app containing more than one function.
The other aim of an app for two-way risk communica-
tion is to increase the number of ADRs reported. A sys-
tematic review showed that a lack of knowledge on which
ADRs to report (e.g. only serious or also less serious) is an
important reason for the under-reporting of ADRs [35].
Although we did not systematically assess factors that
influence the reporting of ADRs in general, it appears that,
among others, a lack of knowledge on (1) the ability to
report and (2) which type of ADRs to report influences
reporting. Therefore, it might be important to provide clear
guidance on which ADRs to report.
Previously, it has been shown that patients are not
always certain whether a symptom could be an ADR
[12–14, 36]. In addition, it has been indicated that patients
may be uncertain about the exact drug causing the ADR
[37]. The current study also shows this uncertainty since it
was suggested by HCPs that a professional should always
assess whether the entered drug or any of the co-medica-
tion caused the ADR. However, this may not be feasible in
clinical practice.
The focus group discussions and face-to-face interviews
revealed discrepancies in several aspects of an app for two-
way risk communication; for instance, whether they want
feedback and the type of feedback after reporting an ADR,
the type of news in the app, and the use of login details. It
is expected that such discrepancies apply to all apps and it
would be prudent to develop an app that the user can
personalise. Personalising options have been reported pre-
viously as an important factor to using an app [38].
4.1 Strengths and Limitations
A strength of our study was the inclusion of a variety of
patients and HCPs from several European countries. As a
result, it is expected that a wide range of influencing factors
to use an app for two-way risk communication will have
been covered. However, each patient or HCP group was
assessed in a different country in which focus group dis-
cussions, face-to-face interviews or both methods were
used. The included population may not fully represent the
targeted patient/HCP population (e.g. there were more
females) or indeed the whole of the potential target
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population for the Web-RADR app (e.g. all patients and
HCPs). The generalisability of our findings is therefore
limited, but as with most qualitative research, the findings
are intended to generate hypotheses that need to be con-
firmed (e.g. in quantitative surveys). Moreover, for prag-
matic reasons both face-to-face interviews and focus group
discussions were used, whereas each method generally
serves a different purpose. In our opinion, both methods
were valuable in our study since potential factors influ-
encing the use of an app for two-way risk communication
were assessed and a prototype version of this app was
tested. By using both methods, each task was thoroughly
evaluated. Another limitation of the study relates to the use
of the UTAUT model as a theoretical model since it has
been tested to assess user acceptance of new technology in
the workplace rather than technology in the healthcare
sector. Although we were able to categorise each of the
detected influencing factors to one of the themes of the
UTAUT model, a previous study on health apps found a
statistically significant association between behavioural
intention and only one theme of the model (i.e. perfor-
mance expectancy) [39]. Therefore, further research should
be conducted to assess the relevance of the other domains
and their interaction with user characteristics included in
the model for the healthcare sector.
4.2 Guidance for Future Studies
Based on this study it appears that there may be differences
(1) between patients and HCPs, (2) within patient and HCP
groups, and/or (3) between countries regarding factors
potentially influencing the use of an app for two-way risk
communication. Therefore, additional, preferably quanti-
tative studies such as survey studies in large groups of
patients and HCPs are advocated to increase knowledge
about the influencing factors on using such an app. In
future studies, several countries should include the same
patient population and/or HCP group to be able to assess
whether differences are due to variations among patients
and/or HCP groups or among countries. We already stated
that additional research could assess the influence of user
characteristics on using an app for two-way risk commu-
nication. Several other suggestions for further research are
as follows.
In our study, patients with a rare disease or HCPs
treating patients with a rare disease and adolescents seemed
to be more concerned about the security of the app than
those with type 2 diabetes and their HCPs. This may be due
to the fact that an individual with a rare disease can be
more easily identified in healthcare data than someone
without a rare disease [40]. A previous study among ado-
lescents also found that high importance was attached to a
safe app [31]. Further studies may determine whether
diverse patient populations and HCP groups differ in their
opinions on the importance of app security or whether such
differences are country-related.
The cost of the app in terms of space on a device was
mentioned only as a factor that negatively influences app
use by adolescents or HCPs treating adolescents in our
study. It might be that this is a particular concern for
younger persons or for people in the UK.
Time constraints were mentioned as an important factor
for not reporting ADRs. This finding has also been shown
in a systematic review [35]. An app for two-way risk
communication may reduce the time needed to complete an
ADR report, but future studies are needed to test whether
an app will indeed increase the reporting of ADRs by
patients and HCPs.
An app for two-way risk communication may also have
unintended effects such as increased non-adherence and
patients not visiting their HCP. Awareness of the possi-
bility of unintended effects is important and future studies
should be conducted to assess such effects.
A quantitative study will also be useful to assess how
many people are interested in an app for two-way risk
communication rather than having separate apps for each
function; the number of people interested in some other
specific functions in an app (e.g. a reminder function); the
type of news people want to receive in such an app;
whether or not people want to receive feedback after
sending a report, and the type of feedback; and preferences
for presenting a patient-reported ADR to someone’s HCP
and/or parent in the case of adolescents.
5 Conclusions
This study identified factors that could influence the use
of a mobile app for two-way risk communication. These
factors concern feedback; storage of ADR reports; and the
type of news provided in the app. More general factors
concern other functions of the app; ease of use; appro-
priate language and attractive layout; the source of the
information in the app and the receiver of information
provided through the app; the security and costs of the
app; and the operating systems on which the app is
available. Further studies are needed to quantify the
influencing factors and determine the differences among
patients and HCPs, between patient and HCP groups, and
between countries with respect to influencing factors to
use a mobile app for two-way risk communication. Also,
further studies are needed to determine how user charac-
teristics influence the direction (positive or negative) of
the identified factors on actual use of the app. Assessing
influencing factors is relevant to foster uptake and con-
tinued use of an app.
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